Dynamic Regulation of Erythropoietin Gene Expression in Mammals

哺乳动物促红细胞生成素基因表达的动态调控

• 批准号: 8442054
• 负责人: Joseph Anthony Garcia
• 金额: --
• 依托单位: VA NORTH TEXAS HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2016-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8442054
• 关键词: Acetate-CoA Ligase; Acetates; Acetyl Coenzyme A; Acetylation; Acetyltransferase; Acute; Adult; Adverse event; Affect; Anemia; Area; Biochemical; Bioinformatics; Bolus Infusion; Cells; Chronic; Communities; Complex; Critical Care; Data; Deacetylase; Deacetylation; Development; Disease; EP300 gene; Endocrine; Ensure; Erythropoietin; Family; Funding; Gene Expression; Gene Targeting; Generations; Goals; Growth; Healthcare; Homeostasis; Hypoxia; Hypoxia Inducible Factor; Individual; Kidney; Link; Lipids; Liver; Malignant Neoplasms; Mammals; Mediating; Mediator of activation protein; Metabolism; Molecular; Molecular Target; Morbidity - disease rate; Mus; Nature; Outcome; Oxygen; Patients; Physiological; Pilot Projects; Play; Post-Translational Protein Processing; Process; Production; Proteins; Publishing; Regulation; Replacement Therapy; Reporting; Repression; Research Personnel; Risk; Risk Factors; Role; Science; Services; Signal Pathway; Signal Transduction; Stress; Testing; Transcription Coactivator; Veterans; bHLH-PAS factor HLF; base; hypoxia inducible factor 1; improved; in vivo; insight; member; mortality; novel; prevent; public health relevance; response; therapeutic target; transcription factor

DESCRIPTION (provided by applicant): Anemia, a common condition in Veteran patients, is a potent risk factor for increased morbidity and mortality when accompanying other disease states. Although therapies for anemia have improved over the past several decades, almost all current therapies involve bolus administration of erythropoietin (epo), an endocrine factor produced in the adult kidney and also in the liver with severe anemia. Non-physiological, bolus epo administration has untoward effects, including a possible increased thrombotic risk as well as an undesirable stimulatory effect on cancer. Understanding how epo is regulated will allow investigators to develop rational therapies besides epo replacement. Our current focus is defining molecular mechanisms regulating epo expression in mammals. Hypoxia Inducible Factor (HIF) transcription factors are a family of molecular mediators that induce the protective cellular response to hypoxia. We were the first to establish that the second HIF member, HIF-2¿, is critical for in vivo epo gene expression. While an essential role of HIF-2¿ in epo regulation is now recognized, the factors responsible for temporal epo gene expression in vivo, or for abnormal repression of epo gene expression in anemia patients, remain poorly understood. We recently identified a novel mechanism of HIF-2 signaling that affects epo regulation. Activity of HIF-1¿, the founding HIF member, is controlled predominantly by changes in protein levels, which is mediated by oxygen-dependent post-translational modifications of the HIF-1¿ protein. However, although the HIF-2¿ protein undergoes the same oxygen-dependent post-translational modifications, this mechanism is not the sole or even major mechanism for controlling HIF-2 signaling. If not the lack of oxygen, what then is the molecular trigger for activating HIF-2¿? Our central hypothesis is that hypoxia triggers changes in intermediary metabolism to effect acetylation of HIF-2¿. In Preliminary Data, we show that HIF-2¿ activity is controlled by two post-translational modifications, acetylation and deacetylation. In Pilot Studies, we identify the molecular and biochemical basis for HIF-2¿ acetylation, termed the acetate switch, which involves changes in intermediary metabolism to induce HIF-2¿ acetylation and coactivator recruitment. Deciphering how the acetate switch regulates HIF-2 signaling will provide novel insights into normal epo regulation and will identify selective molecular targets for modulation of endogenous epo gene expression in patients with anemia.

描述（由申请人提供）： 贫血是退伍军人患者的常见疾病，是伴随其他疾病状态时发病率和死亡率增加的潜在风险因素。虽然贫血的治疗在过去几十年中已经有所改善，但几乎所有目前的治疗都涉及促红细胞生成素（epo）的推注，这是一种在成人肾脏和严重贫血的肝脏中产生的内分泌因子。非生理性的促红细胞生成素大剂量给药具有不良反应，包括可能增加血栓形成的风险以及对癌症的不良刺激作用。了解促红细胞生成素是如何调节的，将使研究人员能够开发出除促红细胞生成素替代外的合理治疗方法。 我们目前的研究重点是确定哺乳动物epo表达的分子调控机制。缺氧诱导因子（HIF）转录因子是一类诱导细胞缺氧保护性反应的分子调节因子。我们是第一个确定第二个HIF成员HIF-2 <$对体内epo基因表达至关重要的人。虽然现在认识到HIF-2在EPO调节中的重要作用，但对体内暂时性EPO基因表达或贫血患者中EPO基因表达异常抑制的因素仍知之甚少。 我们最近发现了一种新的HIF-2信号转导机制，影响EPO的调节。HIF-1的活性HIF-1是HIF的创始成员，主要由蛋白质水平的变化控制，而蛋白质水平的变化是由HIF-1的氧依赖性翻译后修饰介导的。然而，尽管HIF-2蛋白经历相同的氧依赖性翻译后修饰，但这种机制不是控制HIF-2信号传导的唯一甚至主要机制。如果不是缺氧，那么激活HIF-2的分子触发因素是什么？ 我们的中心假设是，缺氧触发中间代谢的变化，影响HIF-2的乙酰化。在初步数据中，我们表明HIF-2的活性是由两个翻译后修饰，乙酰化和脱乙酰化控制的。在初步研究中，我们确定了HIF-2 <$乙酰化的分子和生化基础，称为乙酸开关，它涉及中间代谢的变化，以诱导HIF-2 <$乙酰化和辅激活因子的招募。破译醋酸开关如何调节HIF-2信号将提供新的见解正常EPO调节，并将确定选择性分子靶点调节内源性EPO基因表达贫血患者。